Mantle Cell Lymphoma - Pipeline Insight, 2024

This Mantle Cell Lymphoma - Pipeline Insight, 2024,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Mantle Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Mantle Cell Lymphoma Understanding

Mantle Cell Lymphoma: Overview

Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphomas (NHLs) usually identified by a translocation of the CCND1 gene. The variety of morphologic variants may make this a challenging diagnosis, although most cases are uncomplicated. It typically follows an aggressive clinical course, although an indolent leukemia variant has been described.

MCL is characterized by reciprocal chromosomal translocation t(11;14)(q13:q32), resulting in juxtapositioning of cyclin D1 locus to immunoglobulin heavy chain gene locus. This leads to constitutive expression of cyclin D1 (CCND1), which plays a significant role in tumor cell proliferation via cell cycle dysregulation, chromosomal instability, and epigenetic regulation. Rare cases without this translocation may have a CCND2 or 3 translocations. Hypothetical models of molecular subtypes have been proposed based on the cell of origin that correlates to clinical phenotypes. Arising from naive B cells that have no or limited i GVH mutations and express SOX 11 are the classical MCL or aggressive MCL. SOX 11 is a neural transcription factor reported to block terminal B cell differentiation. Arising from antigen-experienced B cells that have undergone IGVH somatic hypermutations and typically SOX 11 negative and genetically stable B cells are the indolent variant ofMCL
Mantle Cell Lymphoma - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Mantle Cell Lymphoma pipeline landscape is provided which includes the disease overview and Mantle Cell Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Mantle Cell Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Mantle Cell Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence R&D Mantle Cell Lymphoma. The therapies under development are focused on novel approaches to treat/improve Mantle Cell Lymphoma.

Mantle Cell Lymphoma Emerging Drugs

Venetoclax: AbbVie
Venetoclax is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis. VENCLYXTO targets the BCL-2 protein and works to help restore the process of apoptosis.

Venetoclax is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. Together, the companies are committed to BCL-2 research and to studying venetoclax in clinical trials across several blood and other cancers. Venetoclax is approved in more than 80 countries, including the U.S. Currently the product is in Phase III for mantle cell lymphoma.

Daratumumab: Janssen Pharmaceutical
Daratumumab is a first-in-class3 biologic targeting CD38, a surface protein that is highly expressed across multiple myeloma cells, regardless of disease stage.4 Daratumumab is believed to induce tumour cell death through multiple immune-mediated mechanisms of action, including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), as well as through apoptosis, in which a series of molecular steps in a cell lead to its death. Currently the product is in Phase II for the treatment of Mantle Cell Lymphoma.

Mantle Cell Lymphoma: Therapeutic Assessment

This segment of the report provides insights about the Mantle Cell Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Mantle Cell Lymphoma

There are approx. 35+ key companies which are developing the therapies Mantle Cell Lymphoma. The companies which have their Mantle Cell Lymphoma drug candidates in the most advanced stage, i.e phase III include Abbvie

Phases

This report covers around 35+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Mantle Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Mantle Cell Lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Mantle Cell Lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mantle Cell Lymphoma drugs.

Mantle Cell Lymphoma Report Insights

• Mantle Cell Lymphoma Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Mantle Cell Lymphoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Mantle Cell Lymphoma drugs?
• How many Mantle Cell Lymphoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Mantle Cell Lymphoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Mantle Cell Lymphoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Mantle Cell Lymphoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Juno Therapeutics
• Nurix
• Janssen Biotech
• AbbVie/Genentech
• TG Therapeutics
• Roche
• Eli Lilly and Company
• Takeda Oncology
• Starton Therapeutics
• Incyte Corporation
• BeiGene
• Newave Pharmaceutical
• Eli Lilly and Company

Key Products

• Lisocabtagene maraleucel
• NX 5948
• Daratumumab
• Venetoclax
• Ublituximab
• Umbralisib
• Obinutuzumab
• Abemaciclib
• Lenalidomide
• Ixazomib
• Parsaclisib
• BGB 16673
• LP-168
• HMPL-760
• LOXO-338

This product will be delivered within 1-3 business days.